Drug Profile

Research programme: antisense oligonucleotides - Evotec/Secarna Therapeutics

Latest Information Update: 30 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Jul 2024 Preclinical trials in Neurodegenerative disorders in Germany (Parenteral), prior to July 2024 (Secarna Pharmaceuticals pipeline, July 2024)
28 Mar 2024 Bristol Myers Squibb enters into an exclusive global license agreement with Evotec SE for selected late-stage neurodegeneration discovery programmes that were developed and progressed within the collaboration
05 Aug 2020 Evotec SE and Secarna Pharmaceuticals agree to co-develop antisense oligonucleotides

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com